Jun 26, 2025 07:55AM ZyVersa Therapeutics (ZVSA) Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200’s Phase 2a Clinical Trial

Jun 25, 2025 07:55AM ZyVersa Therapeutics (ZVSA) Announces Share Purchase Agreement for up to $10M in Partnership with Williamsburg Venture Holdings

May 20, 2025 08:52AM ZyVersa Therapeutics (ZVSA) Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

May 13, 2025 04:49PM ZyVersa Therapeutics (ZVSA) Misses Q1 EPS by 73c

May 7, 2025 07:57AM ZyVersa Therapeutics (ZVSA) Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Up

Apr 24, 2025 07:57AM ZyVersa Therapeutics (ZVSA) CEO Issues Shareholder Letter

Apr 8, 2025 07:57AM ZyVersa Therapeutics (ZVSA) CEO Issues Shareholder Letter on PARASOL Recommendations

Mar 18, 2025 07:57AM ZyVersa Therapeutics (ZVSA) Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Mode

Mar 12, 2025 07:57AM ZyVersa Therapeutics (ZVSA) Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

Mar 6, 2025 08:00AM ZyVersa Therapeutics (ZVSA) Announces 2.11M Share Offering at $0.95/sh

Mar 5, 2025 07:52AM ZyVersa Therapeutics (ZVSA) Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity

Nov 20, 2024 07:56AM ZyVersa Therapeutics (ZVSA) Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinica

Nov 5, 2024 07:06AM ZyVersa (ZVSA) Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and

Oct 22, 2024 07:57AM ZyVersa Therapeutics (ZVSA) Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Oct 17, 2024 07:50AM ZyVersa Therapeutics (ZVSA) CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Oct 7, 2024 07:55AM ZyVersa Therapeutics (ZVSA) Forms New Scientific Advisory Board

Aug 12, 2024 03:40AM ZyVersa Therapeutics (ZVSA) Tops Q2 EPS by 44c

Aug 7, 2024 07:50AM ZyVersa Therapeutics (ZVSA) Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

Jul 29, 2024 07:45AM ZyVersa Therapeutics (ZVSA) Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

Jul 25, 2024 07:58AM ZyVersa Therapeutics (ZVSA) Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100